Heart failure is a growing epidemic in developed nations. According to the most recent 28
figures from the Centers for Disease Control and Prevention and the 2016 statistical update 29 from the American Heart Association, it is estimated that approximately 1.8% of the US 30 population, approximately 5.8 million adults, have heart failure (4, 8). This is reflected in 31 other nations; for example, in Australia an estimated 1-2% of the population have heart 32 failure (13). Worryingly, in the US alone, it has been forecast that a 46% increase in the 33 prevalence of heart failure will occur during the period from 2012 to 2030. Thus, it is 34 predicted that in the US more than 8 million adults will suffer from heart failure by 2030 (8) . 35 This increase in the prevalence of heart failure has been largely attributed to an aging 36 population, but the increases in the rates of obesity and diabetes, as well as improvements 37 in detection, monitoring and treatment of acute myocardial infarction, are significant 38 factors contributing to this rise (14) . 39
40
Although current therapies for heart have some benefit, they do not prevent the 41 progression of the disease and prognosis remains poor. Thus, there is great interest in the 42 identification of new pathways that can be targeted in heart failure to slow the disease 43 process and thereby reduce morbidity and mortality. One focus of research has been the 44 role of circulating pro-inflammatory cytokines, such as tumor necrosis factor- (TNF-) and 45 interleukins (such as IL-1), the levels of which are elevated in patients with multiple forms of 46 heart failure, including heart failure with reduced and preserved ejection fraction as well as 47 acute decompensated heart failure (6). Increased circulating levels of proinflammatory 48 cytokines (PIC) are associated with adverse outcomes in patients with heart failure; 49 however, the mechanisms by which PICs have detrimental effects remain largely unknown. 50
Over the past decade, several research groups, including that led by Robert Felder, have 51 explored the roles and actions of PICs in the brains of animals with heart failure (12, 15, 16). 52
They showed that peripheral administration of PICs activates the sympathetic nervous 53 system, presumably via a direct central action (16). It is well established that sympathetic 54 overactivity in heart failure is detrimental and contributes to peripheral vasoconstriction 55 and extracellular fluid volume accumulation, which places additional stress on the failing 56 heart leading to further cardiac damage (9). So how do large, hydrophobic peptides such as 57 circulating inflammatory cytokines, which are too big to cross the blood-brain barrier, 58 activate the sympathetic nervous system? Current theories suggest that cytokines, such as 59 offer us a glimpse of a possible new target for heart failure treatment, the brain, via the 123 knockdown of TNFR1 in the SFO. While it is early days and much work is still needed with 124 regard to improving safety and efficacy of viral vector use to treat intractable diseases, viral 125 vector mediated gene delivery is currently being trialled to treat a number of diseases 126 ranging from Leber hereditary optic neuropathy (3) to Alzheimer's disease (11). Despite this 127 rather hopeful outlook, we are nevertheless cognisant of the considerable barriers that 128 need to be surmounted before findings such as these can be translated to the clinic. For 129 example, we need to carefully consider the timing of interventions. Will this treatment be 130 effective in patients with advanced heart failure and can we achieve stable knockdown of 131 the TNFR1 receptor long-term? Do we need cell specific knockdown of TNFR1, perhaps to 132 those cells that project directly to the PVN and are sympathoexcitatory? Would precise 133 targeting be possible given that the SFO is an extremely small structure in humans (7)? 134
Despite these challenges, the sensory circumventricular organs in the brain are attractive 135 sites for targeted therapies due to the absence of a blood-brain barrier. Clearly more animal 136 studies need to be performed to add to our understanding of the brain mechanisms leading 137 to the central generation of increased sympathetic tone in heart failure. We have much 138 work ahead of us; however, work such as that reported by Yu et al., will no doubt drive the 139 future development of novel treatments to reduce morbidity and mortality in heart failure. 
